Strategic tie-up to help Reliance scale up automation across its businesses
The company's net profit stood at Rs 49.9 crore in the year-ago period
The company has allotted over 1.16 crore equity shares to anchor investors at Rs 175 apiece
A report has revealed that about 71 per cent of workers surveyed are rethinking their careers and might explore a different career.
At a closed-door government meeting on Tuesday, Reliance told officials that India needed special regulations to ensure 'non-discriminatory' treatment of sellers on marketplace websites, say sources
BNP Paribas, HDFC Balanced Advantage Fund, Nippon Life India Small Cap Fund and Abakkus Growth Fund among those to have got allotment
Profit up 8.17% sequentially; revenue growth 20% YoY at Rs 1,687 crore
The small-cap firm's current market capitalisation is worth Rs 1,092 crore, exchange data showed
Social Capital Suvretta Holdings Corp. III and ProKidney will have a combined equity value of $2.64 billion, the companies said.
Apple's contract manufacturers in India -- Foxconn and Wistron -- will avail the PLI incentives for the first time this year
Investors can put in as little as Rs 10,000 to fund firms undergoing insolvency
Private equity and venture capital funds invested $77 billion in Indian companies in 2021, a jump of 62 per cent over the previous year, a report said on Tuesday.
Net interest income for Q3FY22 increased by 40% to Rs 6,000 cr
Business Standard brings you the top headlines on Tuesday
Bidding for 15 blocks offered in the first coal-bed methane (CBM) round in more than a decade will start on February 15 and end on March 15, the Directorate General of Hydrocarbons (DGH) said
Raghu Krishnananda, earlier chief technology officer, is now chief technology and product officer (CTPO)
Mining major Coal India Ltd is committed to meet the elevated demand of the dry fuel from the power sector, including coastal plants dependent on imports, a company official said on Tuesday.
A worker union leader said the company management wants to conclude the talks and arrive at a settlement by February 2022
Stempeutics said it has received DCGI clearance to conduct Phase 3 clinical trial on its product for treating COVID-19 patients suffering from acute respiratory distress syndrome (ARDS).
On December 6, 2021, IGESL board approved fund raising through an initial public offer comprising fresh issue of equity shares